Relation of a novel fibrosis marker and post-myocardial infarction left ventricular ejection fraction in...

Area of Science:

• Cardiology
• Biomarker Research
• Medical Diagnostics

Background:

• Myocardial infarction (MI) can lead to impaired left ventricular ejection fraction (LVEF).
• Identifying reliable biomarkers for post-MI cardiac dysfunction is crucial for patient management.
• HE-4, a fibrosis marker, has not been extensively studied in the context of post-STEMI LVEF.

Purpose of the Study:

• To investigate the association between HE-4 levels and LVEF in patients with ST-segment elevation myocardial infarction (STEMI) after revascularization.
• To determine if HE-4 can predict reduced LVEF following STEMI.
• To explore HE-4 as a potential diagnostic marker for cardiac dysfunction post-MI.

Main Methods:

• A cohort of 94 STEMI patients undergoing primary revascularization was studied.
• HE-4 levels were measured at hospital admission and 4 days post-STEMI.
• Transthoracic echocardiography was performed to assess LVEF, with data analyzed using multivariable and ROC analyses.

Main Results:

• HE-4 levels 4 days post-STEMI were significantly higher in patients with low LVEF.
• Higher HE-4 values, along with troponin I, anterior MI, and diabetes, independently predicted low LVEF.
• A negative correlation was observed between changes in HE-4 levels and LVEF, with a HE-4 threshold of 34.01 pmol/l identifying patients with low LVEF.

Conclusions:

• In revascularized STEMI patients, elevated HE-4 levels correlate with decreased LVEF.
• HE-4 demonstrates potential as a diagnostic marker for left ventricular systolic dysfunction after STEMI.
• Further research into HE-4 as a therapeutic target for heart failure post-STEMI is warranted.